Developer docs
API playgroundTry for free, no card

Search company profiles

ProPhase Labs

Full company profile

uuid00045gr

Namestring
ProPhase Labs
Legal namestring
ProPhase Labs, Inc.
Company typeenum
Public
Founded yearint
2018
Descriptiontext

ProPhase Labs is a publicly traded, diversified next-generation biotech, genomics, and consumer products company that operates through three core segments. First, through wholly-owned subsidiaries Nebula Genomics and DNA Complete, the company offers direct-to-consumer whole genome sequencing at three subscription tiers (Essential 1x, Pro 30x, Elite 100x WGS) with up to 350 personalized health and ancestry reports. Second, through ProPhase BioPharma, the company holds the BE-Smart esophageal cancer diagnostic — a CLIA-certified, CAP-accredited 8-protein mass spectrometry assay developed with Mayo Clinic for risk stratification of Barrett's Esophagus patients — plus worldwide exclusive licenses for Linebacker LB-1/LB-2 (PIM kinase cancer co-therapeutics) and Equivir antivirals. Third, TK Supplements distributes consumer health products (Legendz XL, Triple Edge XL) through Walmart, Walgreens, CVS, and Rite-Aid.

The company was historically a consumer health products business (Cold-EEZE was sold to Mylan for $50M); under Chairman and CEO Ted Karkus it pivoted into molecular diagnostics and genomics, acquiring Nebula Genomics for $14.6M in August 2021. That pivot peaked with COVID-19 diagnostic testing revenue of $122.6M in FY2022, followed by sequential contraction to $4.9M in FY2025 as testing demand evaporated. The diagnostics subsidiary filed Chapter 11 in September 2025; the manufacturing subsidiary (Pharmaloz) was divested in January 2025. Current revenue is generated entirely from genomic services and consumer supplements, while a separate Crown Medical Collections initiative pursues recovery of approximately $201.2M in gross COVID testing claims for estimated net recoveries of $50-60M.

The company is now operating in a strategic-alternatives posture: in December 2025 it signed a non-binding LOI for a reverse merger with European biotech Advanced Biological Laboratories (ABL) at a valuation of up to $30M, which would transfer approximately 76% ownership to ABL shareholders and shift the strategic center of gravity to Europe. Concurrently, it has initiated an active sale or strategic partnership process for BE-Smart with outreach to over 70 potential acquirers. The company trades on OTC Markets under ticker PRPH after being downlisted from Nasdaq, and disclosed an unsealed False Claims Act civil lawsuit in the Eastern District of New York.

Short descriptiontext

ProPhase Labs (OTC: PRPH) is a micro-cap biotech operating DTC whole genome sequencing via Nebula Genomics/DNA Complete, the BE-Smart esophageal cancer diagnostic, and TK Supplements consumer products, currently pursuing strategic alternatives including a reverse merger with ABL.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGarden City, United States
HQ citystring
Garden City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
whole genome sequencing, cancer diagnostics, biotech therapeutics, dietary supplements, consumer health products
Industry5 codes
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Diversified Biotech and Genomics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Genomic Products and Services
TypeSubscription Recurring
Description

Whole genome sequencing direct-to-consumer products through Nebula Genomics and DNA Complete, including subscription services for ongoing updates and personalized health reports

ir.prophaselabs.com
2Consumer Products
TypeOne Time License
Description

Sales of TK Supplements products including Legendz XL and Triple Edge XL through retail channels (Walmart, Walgreens, CVS, Rite-Aid) and online

ir.prophaselabs.com
3Crown Medical Collections
TypeTransaction Fee
Description

Recovery of unpaid and underpaid COVID-19 diagnostic testing claims, with estimated net recoveries of $50-60 million from approximately $201.2 million in gross claims

ir.prophaselabs.com
4BE-Smart Esophageal Cancer Test
TypeLicensing Royalties
Description

Potential royalty or participation-based revenue streams from sale or strategic partnership of BE-Smart diagnostic test

ir.prophaselabs.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Others
Pricing details4 tiers
1Essential tier with 1x whole genome sequencing and basic reports
ModelSubscriptionBilling cadenceAnnual
Notes

Essential tier offering 1x whole genome sequencing with the first year of membership included

ir.prophaselabs.com
2Pro tier with 30x whole genome sequencing and expanded reports
ModelSubscriptionBilling cadenceAnnual
Notes

Pro tier offering 30x whole genome sequencing with more than 250 personalized health reports

ir.prophaselabs.com
3Elite tier with 100x whole genome sequencing and comprehensive reports
ModelSubscriptionBilling cadenceAnnual
Notes

Elite tier offering 100x whole genome sequencing with more than 350 personalized health reports

ir.prophaselabs.com
4BE-Smart esophageal cancer test
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Estimated reimbursement rate of $1,000 to $2,000 per test with potential addressable market of $7 billion to $14 billion annually

ir.prophaselabs.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 5 records shown
1Nebula Genomics
Description

Whole genome sequencing and personal genomics services

ir.prophaselabs.com
+4 more records
Core offering1 text field

ProPhase Labs is a diversified biotech, genomics and consumer products company that sells direct-to-consumer whole genome sequencing services through Nebula Genomics and DNA Complete, develops the BE-Smart CLIA-certified esophageal cancer diagnostic test (an 8-protein mass spectrometry assay validated with Mayo Clinic), markets consumer dietary supplements under TK Supplements (Legendz XL, Triple Edge XL), and operates Crown Medical Collections to recover unpaid COVID-19 testing claims from over 250 insurance payors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • BE-Smart demonstrated very high sensitivity for progression prediction in Mayo Clinic pilot study
+4 more records
Product overview1 text field

ProPhase Labs operates as a diversified biotech, genomics and consumer products company with three core business segments: (1) Nebula Genomics and DNA Complete for whole genome sequencing and personalized genomic reports, (2) ProPhase BioPharma developing cancer therapeutics (Linebacker LB-1/LB-2) and antivirals (Equivir), and (3) TK Supplements consumer health products. The company also holds the BE-Smart esophageal cancer diagnostic test and is pursuing Crown Medical Collections for receivables recovery.

Product and service8 records
1Nebula Genomics
CategoryConsumer Genomics / Whole Genome Sequencing
Description

Whole genome sequencing platform providing consumers access to affordable DNA sequencing with over 300 personalized health and ancestry reports delivered through a secure online portal with subscription updates as new scientific discoveries emerge; co-founded by Dr. George Church.

2DNA Complete
CategoryConsumer Genomics / Whole Genome Sequencing
Description

Direct-to-consumer whole genome sequencing platform offering three service tiers (Essential 1x WGS, Pro 30x WGS, Elite 100x WGS) with 175, 250, and 350 personalized health reports respectively; includes DNA Expand feature allowing consumers to upload existing DNA data for enhanced analysis across over 35 million genetic variants.

3BE-Smart Esophageal Cancer Test
CategoryCancer Diagnostics
Description

Laboratory-developed diagnostic test for risk stratification of Barrett's Esophagus patients to esophageal adenocarcinoma; runs on standard FFPE biopsy tissue with no additional procedures required; estimated reimbursement $1,000-$2,000 per test with a $7-14 billion annual addressable market based on 7 million U.S. upper endoscopies per year.

4Legendz XL
CategoryConsumer Dietary Supplements
Description

TK Supplements male sexual enhancement dietary supplement trademarked product sold through Walmart, Walgreens, CVS, Rite-Aid and online.

5Triple Edge XL
CategoryConsumer Dietary Supplements
Description

TK Supplements energy and stamina booster dietary supplement trademarked product sold through Walmart, Walgreens, CVS, Rite-Aid and online.

6Linebacker LB-1 and LB-2
CategoryBiopharmaceutical / Oncology Therapeutics
Description

Modified polyphenol therapeutic compounds developed under worldwide exclusive license from Global BioLife, Inc., targeting PIM kinase for cancer co-therapy combinations with Paclitaxel, Doxorubicin, Topotecan and Cisplatin; under two-year collaborative research agreement with Dana-Farber Cancer Institute and Harvard Medical School across hepatic, colon and breast cancer cell lines.

7Equivir
CategoryAntiviral Dietary Supplements
Description

Broad-based antiviral dietary supplement under worldwide exclusive license from Global BioLife, Inc.; includes an Equivir G prescription variant being commercialized through licensing agreements.

8Crown Medical Collections
CategoryHealthcare Claims Recovery Services
Description

Specialized medical claims collection service pursuing recovery of unpaid and underpaid COVID-19 diagnostic testing claims; covers approximately $201.2 million in gross claims across 649,205 individual claims and 194 open matters with approximately $79.9 million in active settlement negotiations across 250+ insurance payors, with estimated net recoveries of $50-60 million.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-19
Description

Non-binding LOI for proposed reverse merger where ABL shareholders would own approximately 76% of combined entity at valuation of up to $30 million; includes potential $10 million special cash dividend and carve-out of approximately $50 million in receivables

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Partnership using CertisAI Predictive Oncology Intelligence to determine which cancers Linebacker would be most effective against

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-01
Description

Collaboration with Mayo Clinic for continued development of BE-Smart Esophageal Pre-Cancer diagnostic screening test, yielding clinical evidence and publication supporting the 8-protein assay

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-01
Description

Two-year collaborative agreement to further research LB-1, with studies focused on identifying most effective combination of cancer cell lines and agents; initial focus on hepatic, colon and breast cancer

5Dr. George Church
Strategic tierCoreTypeOthers
Description

Co-founder and Advisory Board member of Nebula Genomics; Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org; pioneered development of multiple DNA sequencing methods

ir.prophaselabs.com
6mProbe, Inc.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Independent test lab utilized for BE-Smart test validation on over 200 human samples; precision health company utilizing clinical proteomics in oncology

ir.prophaselabs.com
7Dr. Joe Abdo
Strategic tierCoreTypeOthers
Description

Molecular oncology scientist with 18+ years experience; member of Clinical Science Advisory Board for ProPhase Labs and ProPhase Biopharma; Vice President of Clinical Diagnostics at Oxford BioDynamics

ir.prophaselabs.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

Investor relations firm engaged to lead investor relations efforts and increase visibility with institutional and retail investors

Strategic tierMinorTypeGTM or Marketing Partner
Description

Continues hosting earnings calls and virtual road shows for ProPhase Labs

10Crown Medical Collections, LLC
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Specialized medical collections firm serving as special counsel to ProPhase's laboratory subsidiaries for recovery of COVID-19 testing claims

ir.prophaselabs.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Sales agreement relating to shares for at-the-market offering

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Ancestry
TypeDirect peer
Description

Largest DTC genealogy and consumer genomics brand; competes with Nebula/DNA Complete in the consumer DNA testing and ancestry category.

2mProbe
TypeDirect peer
Description

Clinical proteomics company specializing in oncology biomarker assays; partnered with ProPhase on BE-Smart validation and operates in the same proteomics-driven cancer testing niche.

TypeDirect peer
Description

Direct-to-consumer genetic testing company offering ancestry and health reports, directly comparable to Nebula Genomics and DNA Complete in the consumer WGS/genotyping category.

TypeDirect peer
Description

Commercial-stage cancer diagnostics company (Cologuard, Oncotype DX) with strong gastroenterology channel overlap to BE-Smart and a similar biomarker-based testing business model.

TypeDirect peer
Description

Specialized cancer diagnostics company commercializing proprietary tissue-based tests; comparable to BE-Smart's CLIA-certified LDT positioning and oncology risk-stratification model.

TypeDirect peer
Description

Whole genome sequencing company with consumer and clinical offerings, directly comparable to Nebula Genomics/DNA Complete in the WGS-as-a-service category.

TypeDirect peer
Description

Clinical and population-scale genetic testing platform offering hereditary cancer and whole genome tests; competes with Nebula/DNA Complete in DTC-adjacent and clinical genomics.

TypeBroad incumbent
Description

Established liquid biopsy and oncology diagnostics company with broader cancer portfolio; comparable as a cancer diagnostics incumbent pursuing biomarker-led oncology tests similar to BE-Smart.

TypeDirect peer
Description

Molecular diagnostics company using proprietary biomarker platforms in oncology; comparable to BE-Smart's proteomics/molecular test positioning, and home to ProPhase advisor Dr. Joe Abdo.

TypeDirect peer
Description

DTC ancestry and health genetic testing company serving global consumers; directly comparable to Nebula/DNA Complete in DTC genetic reports.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProPhase Labs

Diversified Biotech and Genomicsprophaselabs.com

ProPhase Labs (OTC: PRPH) is a micro-cap biotech operating DTC whole genome sequencing via Nebula Genomics/DNA Complete, the BE-Smart esophageal cancer diagnostic, and TK Supplements consumer products, currently pursuing strategic alternatives including a reverse merger with ABL.

What ProPhase Labs does

ProPhase Labs is a publicly traded, diversified next-generation biotech, genomics, and consumer products company that operates through three core segments. First, through wholly-owned subsidiaries Nebula Genomics and DNA Complete, the company offers direct-to-consumer whole genome sequencing at three subscription tiers (Essential 1x, Pro 30x, Elite 100x WGS) with up to 350 personalized health and ancestry reports. Second, through ProPhase BioPharma, the company holds the BE-Smart esophageal cancer diagnostic — a CLIA-certified, CAP-accredited 8-protein mass spectrometry assay developed with Mayo Clinic for risk stratification of Barrett's Esophagus patients — plus worldwide exclusive licenses for Linebacker LB-1/LB-2 (PIM kinase cancer co-therapeutics) and Equivir antivirals. Third, TK Supplements distributes consumer health products (Legendz XL, Triple Edge XL) through Walmart, Walgreens, CVS, and Rite-Aid.

The company was historically a consumer health products business (Cold-EEZE was sold to Mylan for $50M); under Chairman and CEO Ted Karkus it pivoted into molecular diagnostics and genomics, acquiring Nebula Genomics for $14.6M in August 2021. That pivot peaked with COVID-19 diagnostic testing revenue of $122.6M in FY2022, followed by sequential contraction to $4.9M in FY2025 as testing demand evaporated. The diagnostics subsidiary filed Chapter 11 in September 2025; the manufacturing subsidiary (Pharmaloz) was divested in January 2025. Current revenue is generated entirely from genomic services and consumer supplements, while a separate Crown Medical Collections initiative pursues recovery of approximately $201.2M in gross COVID testing claims for estimated net recoveries of $50-60M.

The company is now operating in a strategic-alternatives posture: in December 2025 it signed a non-binding LOI for a reverse merger with European biotech Advanced Biological Laboratories (ABL) at a valuation of up to $30M, which would transfer approximately 76% ownership to ABL shareholders and shift the strategic center of gravity to Europe. Concurrently, it has initiated an active sale or strategic partnership process for BE-Smart with outreach to over 70 potential acquirers. The company trades on OTC Markets under ticker PRPH after being downlisted from Nasdaq, and disclosed an unsealed False Claims Act civil lawsuit in the Eastern District of New York.

ProPhase Labs firmographics

Firmographics
Name
ProPhase Labs
Legal name
ProPhase Labs, Inc.
Website
https://prophaselabs.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
ProPhase Labs (OTC: PRPH) is a micro-cap biotech operating DTC whole genome sequencing via Nebula Genomics/DNA Complete, the BE-Smart esophageal cancer diagnostic, and TK Supplements consumer products, currently pursuing strategic alternatives including a reverse merger with ABL.
Ownership category
akta.pro rank

ProPhase Labs industry classification

Industry
Product category
Diversified Biotech and Genomics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Whole genome sequencing
  • Cancer diagnostics
  • Biotech therapeutics
  • Dietary supplements
  • Consumer health products

Where ProPhase Labs is headquartered

Location

Headquarters

HQ city
Garden City
HQ country
United States
HQ region
North America

Offices4 records

Markets served

ProPhase Labs business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Genomic Products and Services: Whole genome sequencing direct-to-consumer products through Nebula Genomics and DNA Complete, including subscription services for ongoing updates and personalized health reports
  2. Consumer Products: Sales of TK Supplements products including Legendz XL and Triple Edge XL through retail channels (Walmart, Walgreens, CVS, Rite-Aid) and online
  3. Crown Medical Collections: Recovery of unpaid and underpaid COVID-19 diagnostic testing claims, with estimated net recoveries of $50-60 million from approximately $201.2 million in gross claims
  4. BE-Smart Esophageal Cancer Test: Potential royalty or participation-based revenue streams from sale or strategic partnership of BE-Smart diagnostic test

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEssential tier with 1x whole genome sequencing and basic reports
SubscriptionAnnualPro tier with 30x whole genome sequencing and expanded reports
SubscriptionAnnualElite tier with 100x whole genome sequencing and comprehensive reports
Unit PricingPay-as-you-goBE-Smart esophageal cancer test

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

ProPhase Labs product offering

Product offering

Core offering

ProPhase Labs is a diversified biotech, genomics and consumer products company that sells direct-to-consumer whole genome sequencing services through Nebula Genomics and DNA Complete, develops the BE-Smart CLIA-certified esophageal cancer diagnostic test (an 8-protein mass spectrometry assay validated with Mayo Clinic), markets consumer dietary supplements under TK Supplements (Legendz XL, Triple Edge XL), and operates Crown Medical Collections to recover unpaid COVID-19 testing claims from over 250 insurance payors.

Product overview

ProPhase Labs operates as a diversified biotech, genomics and consumer products company with three core business segments: (1) Nebula Genomics and DNA Complete for whole genome sequencing and personalized genomic reports, (2) ProPhase BioPharma developing cancer therapeutics (Linebacker LB-1/LB-2) and antivirals (Equivir), and (3) TK Supplements consumer health products. The company also holds the BE-Smart esophageal cancer diagnostic test and is pursuing Crown Medical Collections for receivables recovery.

Differentiator

Problem solved

Functional benefit

Brands

  • Nebula Genomics: Whole genome sequencing and personal genomics services
  • DNA Complete
  • ProPhase BioPharma
  • TK Supplements
  • BE-Smart

Products and services

  • Nebula Genomics Whole genome sequencing platform providing consumers access to affordable DNA sequencing with over 300 personalized health and ancestry reports delivered through a secure online portal with subscription updates as new scientific discoveries emerge; co-founded by Dr. George Church.
  • DNA Complete Direct-to-consumer whole genome sequencing platform offering three service tiers (Essential 1x WGS, Pro 30x WGS, Elite 100x WGS) with 175, 250, and 350 personalized health reports respectively; includes DNA Expand feature allowing consumers to upload existing DNA data for enhanced analysis across over 35 million genetic variants.
  • BE-Smart Esophageal Cancer Test Laboratory-developed diagnostic test for risk stratification of Barrett's Esophagus patients to esophageal adenocarcinoma; runs on standard FFPE biopsy tissue with no additional procedures required; estimated reimbursement $1,000-$2,000 per test with a $7-14 billion annual addressable market based on 7 million U.S. upper endoscopies per year.
  • Legendz XL TK Supplements male sexual enhancement dietary supplement trademarked product sold through Walmart, Walgreens, CVS, Rite-Aid and online.
  • Triple Edge XL TK Supplements energy and stamina booster dietary supplement trademarked product sold through Walmart, Walgreens, CVS, Rite-Aid and online.
  • Linebacker LB-1 and LB-2 Modified polyphenol therapeutic compounds developed under worldwide exclusive license from Global BioLife, Inc., targeting PIM kinase for cancer co-therapy combinations with Paclitaxel, Doxorubicin, Topotecan and Cisplatin; under two-year collaborative research agreement with Dana-Farber Cancer Institute and Harvard Medical School across hepatic, colon and breast cancer cell lines.
  • Equivir Broad-based antiviral dietary supplement under worldwide exclusive license from Global BioLife, Inc.; includes an Equivir G prescription variant being commercialized through licensing agreements.
  • Crown Medical Collections Specialized medical claims collection service pursuing recovery of unpaid and underpaid COVID-19 diagnostic testing claims; covers approximately $201.2 million in gross claims across 649,205 individual claims and 194 open matters with approximately $79.9 million in active settlement negotiations across 250+ insurance payors, with estimated net recoveries of $50-60 million.

Quantifiable outcome

  • BE-Smart demonstrated very high sensitivity for progression prediction in Mayo Clinic pilot study
  • +4 more outcomes

Companies that use ProPhase Labs

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

ProPhase Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ProPhase Labs partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Advanced Biological Laboratories (ABL)coreStrategic or Co-development Partner · 19 December 2025Non-binding LOI for proposed reverse merger where ABL shareholders would own approximately 76% of combined entity at valuation of up to $30 million; includes potential $10 million special cash dividend and carve-out of approximately $50 million in receivables
  • Certis OncologyminorStrategic or Co-development Partner · 1 August 2023Partnership using CertisAI Predictive Oncology Intelligence to determine which cancers Linebacker would be most effective against
  • Mayo Clinic (Dr. Christopher Hartley)coreStrategic or Co-development Partner · 1 March 2023Collaboration with Mayo Clinic for continued development of BE-Smart Esophageal Pre-Cancer diagnostic screening test, yielding clinical evidence and publication supporting the 8-protein assay
  • Dana-Farber Cancer Institute and Harvard Medical SchoolcoreStrategic or Co-development Partner · 1 November 2022Two-year collaborative agreement to further research LB-1, with studies focused on identifying most effective combination of cancer cell lines and agents; initial focus on hepatic, colon and breast cancer
  • Dr. George ChurchcoreOthersCo-founder and Advisory Board member of Nebula Genomics; Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org; pioneered development of multiple DNA sequencing methods
  • mProbe, Inc.coreStrategic or Co-development PartnerIndependent test lab utilized for BE-Smart test validation on over 200 human samples; precision health company utilizing clinical proteomics in oncology
  • Dr. Joe AbdocoreOthersMolecular oncology scientist with 18+ years experience; member of Clinical Science Advisory Board for ProPhase Labs and ProPhase Biopharma; Vice President of Clinical Diagnostics at Oxford BioDynamics
  • RedChip CompaniescoreGTM or Marketing PartnerInvestor relations firm engaged to lead investor relations efforts and increase visibility with institutional and retail investors
  • Renmark Financial CommunicationsminorGTM or Marketing PartnerContinues hosting earnings calls and virtual road shows for ProPhase Labs
  • Crown Medical Collections, LLCcoreImplementation/ SI/ Consulting PartnerSpecialized medical collections firm serving as special counsel to ProPhase's laboratory subsidiaries for recovery of COVID-19 testing claims
  • WestPark CapitalminorChannel Partner/ Reseller/ DistributorSales agreement relating to shares for at-the-market offering

Scale indicators15 records

Recent moves10 records

Expansion highlights5 records

ProPhase Labs competitors and assessment

Company assessment

Direct peers

  • Ancestry: Largest DTC genealogy and consumer genomics brand; competes with Nebula/DNA Complete in the consumer DNA testing and ancestry category.
  • mProbe: Clinical proteomics company specializing in oncology biomarker assays; partnered with ProPhase on BE-Smart validation and operates in the same proteomics-driven cancer testing niche.
  • 23andMe: Direct-to-consumer genetic testing company offering ancestry and health reports, directly comparable to Nebula Genomics and DNA Complete in the consumer WGS/genotyping category.
  • Exact Sciences: Commercial-stage cancer diagnostics company (Cologuard, Oncotype DX) with strong gastroenterology channel overlap to BE-Smart and a similar biomarker-based testing business model.
  • Castle Biosciences: Specialized cancer diagnostics company commercializing proprietary tissue-based tests; comparable to BE-Smart's CLIA-certified LDT positioning and oncology risk-stratification model.
  • Veritas Genetics: Whole genome sequencing company with consumer and clinical offerings, directly comparable to Nebula Genomics/DNA Complete in the WGS-as-a-service category.
  • Color: Clinical and population-scale genetic testing platform offering hereditary cancer and whole genome tests; competes with Nebula/DNA Complete in DTC-adjacent and clinical genomics.
  • Oxford BioDynamics: Molecular diagnostics company using proprietary biomarker platforms in oncology; comparable to BE-Smart's proteomics/molecular test positioning, and home to ProPhase advisor Dr. Joe Abdo.
  • MyHeritage: DTC ancestry and health genetic testing company serving global consumers; directly comparable to Nebula/DNA Complete in DTC genetic reports.

Broad incumbents

  • Guardant Health: Established liquid biopsy and oncology diagnostics company with broader cancer portfolio; comparable as a cancer diagnostics incumbent pursuing biomarker-led oncology tests similar to BE-Smart.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

ProPhase Labs social profiles

Digital presence

ProPhase Labs compliance and trust

Trust signal

Compliance4 records

ProPhase Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProPhase Labs leadership team

Management profile

Number of profiles

Profiles7 records

ProPhase Labs subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

ProPhase Labs funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProPhase Labs M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProPhase Labs

What does ProPhase Labs do?

ProPhase Labs is a diversified biotech, genomics and consumer products company that sells direct-to-consumer whole genome sequencing services through Nebula Genomics and DNA Complete, develops the BE-Smart CLIA-certified esophageal cancer diagnostic test (an 8-protein mass spectrometry assay validated with Mayo Clinic), markets consumer dietary supplements under TK Supplements (Legendz XL, Triple Edge XL), and operates Crown Medical Collections to recover unpaid COVID-19 testing claims from over 250 insurance payors.

Is ProPhase Labs a public or private company?

ProPhase Labs is a public company. It is classified as public and is currently operating.

When was ProPhase Labs founded?

ProPhase Labs was founded in 2018. It employs 11 to 50 people.

Where is ProPhase Labs based?

ProPhase Labs is headquartered in Garden City, United States, in the North America region.

How does ProPhase Labs make money?

Four revenue lines are on record. Genomic Products and Services are the primary driver. The others are consumer Products, crown Medical Collections and BE-Smart Esophageal Cancer Test.

Who are ProPhase Labs's main competitors?

Direct peers on record are Ancestry, mProbe, 23andMe, Exact Sciences, Castle Biosciences, Veritas Genetics, Color, Oxford BioDynamics and MyHeritage. Guardant Health is listed as a broad incumbent.

Does ProPhase Labs have an API?

No public API is recorded for ProPhase Labs.

What industry is ProPhase Labs in?

ProPhase Labs's product category is Diversified Biotech and Genomics. Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services, with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Markets DailyComparing Aurora Cannabis (NASDAQ:ACB) and ProPhase Labs (NASDAQ:PRPH)A comparison of Aurora Cannabis and ProPhase Labs shows Aurora has higher revenue ($314.07M vs $5.05M) and lower P/E, but ProPhase has higher earnings per share. Aurora beats ProPhase on 10 of 13 factors, including institutional ownership and profitability.American Banking and Market NewsAurora Cannabis (NASDAQ:ACB) & ProPhase Labs (NASDAQ:PRPH) Financial ComparisonAurora Cannabis and ProPhase Labs are compared on financial metrics, analyst ratings, and ownership. Aurora Cannabis beats ProPhase Labs on 11 of 14 factors, including profitability and institutional ownership. Aurora Cannabis is trading at a lower price-to-earnings ratio, making it the more affordable stock.Markets DailyAnalyzing ProPhase Labs (NASDAQ:PRPH) and Takeda Pharmaceutical (NYSE:TAK)ProPhase Labs and Takeda Pharmaceutical are compared on institutional ownership, risk, dividends, profitability, analyst ratings, earnings, and valuation. Takeda beats ProPhase on 8 of 13 factors, including profitability and analyst ratings, while ProPhase trades at a lower price-to-earnings ratio.Defense WorldComparing ProPhase Labs (NASDAQ:PRPH) and Aurora Cannabis (NASDAQ:ACB)A comparison of ProPhase Labs and Aurora Cannabis evaluates institutional ownership, valuation, earnings, and analyst ratings. Aurora Cannabis beats ProPhase Labs on 11 of 14 factors, with higher revenue and lower P/E ratio. Aurora Cannabis is the more affordable stock.American Banking and Market NewsContrasting ProPhase Labs (NASDAQ:PRPH) and Takeda Pharmaceutical (NYSE:TAK)Takeda Pharmaceutical and ProPhase Labs are compared on 14 factors, with Takeda winning 10. Takeda has higher revenue ($28.32B vs $5.05M) and lower volatility, while ProPhase trades at a lower P/E ratio. Takeda's beta is -0.07, indicating lower volatility than the S&P 500.American Banking and Market NewsProPhase Labs (NASDAQ:PRPH) vs. Adherex Technologies (NASDAQ:FENC) Head to Head ReviewAdherex Technologies (Fennec Pharmaceuticals) outperforms ProPhase Labs on 13 of 14 factors, including higher revenue, lower P/E, and stronger analyst ratings. Adherex's consensus target price of $17.00 implies a 60.38% upside, while ProPhase's is lower. The comparison highlights Adherex's superior profitability and institutional ownership.American Banking and Market NewsAnalyzing ProPhase Labs (NASDAQ:PRPH) & Nutriband (NASDAQ:NTRB)ProPhase Labs and Nutriband are compared on valuation, dividends, analyst ratings, risk, earnings, profitability, and institutional ownership. Nutriband beats ProPhase Labs on 9 of 12 factors, including lower P/E and higher earnings, though it has lower revenue. Nutriband's beta of 2.03 indicates higher volatility than ProPhase's 0.06.AD HOC NEWSProPhase Labs Inc explores growth opportunities in diagnostics and consumer healthProPhase Labs Inc is a US-based healthcare company that has expanded from its origins in over-the-counter consumer health products into diagnostics and testing services, leveraging its existing infrastructure and regulatory experience to build new revenue streams. The company's dual business model combines legacy consumer products sold through retail and wholesale channels with diagnostic services that generate income through testing fees and related contracts. The article provides background on the company's strategic considerations, including balancing capital allocation between legacy operations and newer diagnostic initiatives while managing regulatory compliance and competitive positioning in the US healthcare market.Stock TitanProPhase Labs sees $50M-$60M Crown recoveriesProPhase Labs reported year-end 2025 financial results on April 15, 2026, showing a 27.6% decline in net revenue to $4.9 million and a narrowed net loss of $13.4 million compared to a $53.4 million loss in 2024. The company's Crown Medical Collections portfolio has expanded to $201.2 million in gross claims across 649,205 claims and 194 open matters, with $79.9 million in active settlement negotiations, supporting estimated net recoveries of $50-60 million. Management expects meaningful cash flow from settlements to begin in Q3 2026 and is pursuing receivables-based financing with institutional capital providers.Defense WorldProPhase Labs (NASDAQ:PRPH) versus Medicure (OTCMKTS:MCUJF) Financial ContrastThis article compares two small-cap medical companies, ProPhase Labs (NASDAQ:PRPH) and Medicure (OTCMKTS:MCUJF), across 12 financial metrics including revenue, earnings, valuation, volatility, and profitability. Medicure outperforms ProPhase Labs on 9 of the 12 factors compared, reporting higher revenue of $15.99 million versus $5.06 million and lower net losses. Both companies are currently unprofitable, though ProPhase Labs has significantly larger losses at $53.36 million compared to Medicure's $760,000 loss.